Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio

Key Points

• This research aims to assess the effectiveness of p-tau217 to β-amyloid plasma ratio cut points in identifying amyloid pathology linked to Alzheimer disease.
• Cross-sectional study design
• Evaluation of FDA-cleared phosphorylated tau 217 (p-tau217) to β-amyloid 42 ratio
• Focus on detecting amyloid pathology in relation to Alzheimer disease
• From the evaluated population, variability was observed in the performance of p-tau217 to β-amyloid ratio in detecting amyloid pathology.
• Specific cut points associated with varied sensitivity and specificity for Alzheimer disease diagnosis.